Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert


Search Title by author or title

Clinical outcomes of enVista® intraocular lens in cataract patients

Poster Details

First Author: A.Young HONG KONG

Co Author(s):    G. Siu                    

Abstract Details


Envista® (MX60 - Bausch Lomb) is a hydrophobic acrylic, biconvex symmetrical aspheric intraocular lens (IOL). For our hospital, the first patients received this IOL from January 2014 on. The aim of the study is to review the clinical outcome of patients who received implantation of this IOL.


This is a retrospective study carried out at the Prince of Wales Hospital, Hong Kong, which is a tertiary referral university teaching ophthalmic centre


All patients with MX60 IOL implantation from January 2014 till Aug 2016 were retrieved. Only patients without coexistent ocular pathology were evacuated. The following data was captured: preoperative uncorrected distant visual acuity, best documented distant visual acuity, biometry by ultrasound or IOL Master, target postoperative refraction; postoperative uncorrected distant visual acuity and best documented distant visual acuity at 0-60 days, 61-180 days, 181-365 days and 366-730 days, intraoperative complications, adverse effects, secondary intervention, time of posterior capsular opacification and glistening.


A total of 140 eyes were identified based on the above criteria. 62 were male and 78 were female (55.7%). The average age of the patients were 75 +/ - 10.3. There was one posterior capsular rupture. At 0-60 days, 11/140(7.86%) had a BCVA of 20/20 or better, and 102/140 (72.86%) were 20/40 or better. 18 out of 138 eyes had posterior capsular opacification in which 5 needed Nd:YAG capsulotomy while none had glistening. 1 patient had cystoid macular oedema postoperatively.


Envista® (Mx60) was found to be safe and effective IOL for our cataract patients.

Financial Disclosure:


Back to Poster listing